Novo Nordisk Wegovy Pill Expands GLP-1 Access
Novo Nordisk Wegovy pill launch, low cash pricing and wide pharmacy reach could speed conversion from compounded alternatives and pressure payer coverage.
KEY TAKEAWAYS
- Launched after FDA approval with distribution at more than 70,000 U.S. pharmacies.
- CEO flagged roughly 1.5 million U.S. patients using compounded GLP-1 alternatives.
- Novo expects oral GLP-1s could comprise more than one-third of the market by 2030.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Novo Nordisk said on Jan. 12 that the Novo Nordisk Wegovy pill, launched in early January 2026 after FDA approval in December 2025, carries pricing and pharmacy distribution designed to broaden access to oral GLP‑1 treatments.
U.S. Launch, Trial Results, and Market Outlook
The U.S. Food and Drug Administration approved the oral Wegovy (semaglutide) tablet in December 2025 for chronic weight management and to reduce major cardiovascular events in certain patients. Novo Nordisk launched the once-daily pill shortly after, making it available at more than 70,000 pharmacies and through telehealth platforms. The tablet is taken on an empty stomach with minimal water. The initial 1.5 mg starter dose is priced at $149 per month for cash payers, while higher strengths up to 25 mg are priced at $299 per month, with additional doses scheduled to roll out soon.
In clinical trials, the highest oral dose produced about 14.0% body-weight loss at 64 weeks, roughly 12 percentage points more than placebo. A rival oral candidate reported 12.4% weight loss at 72 weeks, though no direct comparison exists between the two programs.
Novo Nordisk CEO Mike Doustdar noted that about 1.5 million U.S. patients currently use cheaper, unapproved compounded GLP-1 drugs. The company expects oral pills to broaden uptake among patients deterred by needles, refrigeration requirements, or social stigma, projecting that oral GLP-1s could capture more than one-third of the overall market by 2030. At the same time, some patients are expected to prefer weekly injectables over daily tablets.
The company presents the pill’s cash price as lower than many injectable alternatives and estimates insured patients may face roughly $25 per month in out-of-pocket costs, which it views as a path to wider insured adoption. An analyst estimate projects oral pills could capture about 25.0% of the roughly $150 billion obesity market. Rival manufacturers pursuing oral GLP-1 approvals, including Eli Lilly’s oral candidate orforglipron, which is seeking expedited FDA review with potential approval early in 2026, could increase near-term approval and commercial competition.
